[go: up one dir, main page]

RU94012067A - Agent for treatment of complication after insulin-dependent and insulin-independent diabetes mellitus therapy - Google Patents

Agent for treatment of complication after insulin-dependent and insulin-independent diabetes mellitus therapy

Info

Publication number
RU94012067A
RU94012067A RU94012067/14A RU94012067A RU94012067A RU 94012067 A RU94012067 A RU 94012067A RU 94012067/14 A RU94012067/14 A RU 94012067/14A RU 94012067 A RU94012067 A RU 94012067A RU 94012067 A RU94012067 A RU 94012067A
Authority
RU
Russia
Prior art keywords
insulin
treatment
diabetes mellitus
taufon
complication
Prior art date
Application number
RU94012067/14A
Other languages
Russian (ru)
Other versions
RU2054936C1 (en
Inventor
Е.П. Елизарова
Т.Ю. Мизина
Л.В. Недосугова
М.И. Балаболкин
Л.И. Митькина
Ц.Р. Орлова
В.И. Петров
Original Assignee
Е.П. Елизарова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Е.П. Елизарова filed Critical Е.П. Елизарова
Priority to RU94012067A priority Critical patent/RU2054936C1/en
Application granted granted Critical
Publication of RU2054936C1 publication Critical patent/RU2054936C1/en
Publication of RU94012067A publication Critical patent/RU94012067A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: medicine, endocrinology. SUBSTANCE: invention proposes the use of the known preparation taufon for treatment of diabetes mellitus complications of the first and second types (hyperglycemia, glycemic modulations, vessel complications). Taufon tablets have taurine-2-aminoethanesulfonic acid (natural metabolite of sulfur-containing amino acid) as an active substance. EFFECT: enhanced effectiveness of treatment.

Claims (1)

Изобретение относится к области медицины, конкретно к препаратам для лечения сахарного диабета. Сущность изобретения состоит в применении ранее известного препарата тауфон по новым показаниям, а именно для лечения осложнений сахарного диабета первого и второго типа (гипергликемия, гликемические колебания, сосудистые осложнения). Таблетки тауфона содержат в качестве действующего начала таурин-2-аминоэтансульфоновую кислоту, естественный продукт обмена серусодержащих кислот.The invention relates to medicine, specifically to drugs for the treatment of diabetes. The essence of the invention consists in the use of the previously known taufon preparation according to new indications, namely for the treatment of complications of diabetes mellitus of the first and second type (hyperglycemia, glycemic fluctuations, vascular complications). Taufon tablets contain taurine-2-aminoethanesulfonic acid, a natural metabolic product of sulfur-containing acids, as an active ingredient.
RU94012067A 1994-04-07 1994-04-07 Membrane-stabilizing agent for treatment of patient with insulin-dependent and insulin-independent diabetes mellitus RU2054936C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94012067A RU2054936C1 (en) 1994-04-07 1994-04-07 Membrane-stabilizing agent for treatment of patient with insulin-dependent and insulin-independent diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94012067A RU2054936C1 (en) 1994-04-07 1994-04-07 Membrane-stabilizing agent for treatment of patient with insulin-dependent and insulin-independent diabetes mellitus

Publications (2)

Publication Number Publication Date
RU2054936C1 RU2054936C1 (en) 1996-02-27
RU94012067A true RU94012067A (en) 1997-03-20

Family

ID=20154449

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94012067A RU2054936C1 (en) 1994-04-07 1994-04-07 Membrane-stabilizing agent for treatment of patient with insulin-dependent and insulin-independent diabetes mellitus

Country Status (1)

Country Link
RU (1) RU2054936C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
AU2000265516A1 (en) * 2000-08-11 2002-02-25 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
EP2408443A1 (en) 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
RU2493841C1 (en) * 2012-10-09 2013-09-27 Станислав Анатольевич Кедик Synergetic preparation for treating cardiovascular diseases, diabetes mellitus and hepatobiliary diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination

Also Published As

Publication number Publication date
RU2054936C1 (en) 1996-02-27

Similar Documents

Publication Publication Date Title
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
CA2185119A1 (en) Dosage form for administering drug in liquid formulation
EE03292B1 (en) Multiple drug formulation containing a proton pump inhibitor and process for its preparation
RU94022479A (en) Use of antiestrogenic compounds and pharmaceutically acceptable salts and solvents for blood glucose concentration decrease, pharmaceutical preparation
DE69829721D1 (en) Use of activated protein C for the treatment of excessive blood clotting in sepsis
AU4185696A (en) Increasing creatine and glycogen concentration in muscle
ATE202926T1 (en) PHARMACEUTICAL EFFECTIVE PREPARATIONS CONTAINING BIODEGRADABLE MICROCAPSULES FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS
Borowski et al. Blood pressure response to thyrotropin-releasing hormone in euthyroid subjects
ES2101866T3 (en) LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
Fleming et al. Cutaneous insulin reaction resembling acanthosis nigricans
RU99120189A (en) DRUGS FOR TREATMENT OF A METABOLIC SYNDROME CONTAINING A HUMAN GROWTH HORMONE IN COMBINATION WITH A CORTZOL SYNTHESIS INHIBITOR
Adnitt Hypoglycemic action of monoamineoxidase inhibitors (MAOI'S)
RU94012067A (en) Agent for treatment of complication after insulin-dependent and insulin-independent diabetes mellitus therapy
CA2113856A1 (en) Antidiabetic Agent
KR890004690A (en) Use of bezafibraid for the treatment of diabetes
KR940005283A (en) Drugs containing glycentin as active ingredient
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
RU94006580A (en) Adaptogen trecresan in medicine
NO178784B (en) Process for the preparation of a transdermal therapeutic system with norpseudoephedrine as active ingredient
AU2004211961B2 (en) Method for treating hypothyroidism
Gelvin et al. Results of addition of liothyronine to a weight-reducing regimen
KR20000057371A (en) Topical preparation for introducing peptidaceous pharmacons in living organisms
CN1065430C (en) Wart curing paste
Cohen One year of sodium dextrothyroxine therapy for hypercholesterolemia

Legal Events

Date Code Title Description
QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20010712

Effective date: 20110606